

1 **Contribution of infection and vaccination to seroprevalence**
2 **through two COVID waves in Tamil Nadu, India**

3
4 Selvavinayagam T.S.¹ (MD, DPH, DNB), Somasundaram A.² (MD, DPH, MAE), Jerard Maria
5 Selvam¹ (MD), Sabareesh Ramachandran³, (MS economics), Sampath P.¹ (MBBS, DPH),
6 Vijayalakshmi V.¹ (MBBS, DPH, MPH), Ajith Brabhu Kumar C.¹ (MBBS, MD), Sudharshini
7 Subramaniam² (MBBS, MD), Parthipan K. (MBBS, MD),¹ Raju S.¹ (PhD), Avudaiselvi R.¹
8 (MBBS, MD), Prakash V.¹ (MBBS, MPH), Yogananth N.¹ (MBBS, MPH), Gurunathan
9 Subramanian¹ (PhD), Roshini A.¹ (MBBS), Dhiliban D.N.¹ (MBBS), Sofia Imad⁴ (MA,
10 international relations; MA, public health), Vaidehi Tandel⁵ (MA, PhD economics), Rajeswari
11 Parasa⁴ (BS geoinformatics), Stuti Sachdeva⁶ (MPA), Anup Malani⁶ (MA, PhD economics, JD)

12
13 ¹Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu, Chennai,
14 Tamil Nadu, India

15 ²Institute of Community Medicine, Chennai, Tamil Nadu, India

16 ³University of California, San Diego, California, USA:

17 ⁴Artha Global, Mumbai, Maharashtra, India

18 ⁵Henley Business School, University of Reading, Reading, UK

19 ⁵Independent

20 ⁶University of Chicago, Chicago, Illinois, USA

21
22 **Corresponding author:** Anup Malani, University of Chicago, 1111 E. 60th Street, Chicago, IL
23 60637; (773) 702-9602; (773) 702-0730 (fax), amalani@uchicago.edu.

24 **Article Summary Line:** Antibodies waned after India’s first COVID wave and both vaccination
25 and infection contributed its roughly 90% seroprevalence after its second wave.

26

27 **Abstract:** Four rounds of serological surveys were conducted, spanning two COVID waves
28 (October 2020 and April-May 2021), in Tamil Nadu (population 72 million) state in India. Each
29 round included representative populations in each district of the state, totaling $\geq 20,000$ persons
30 per round. State-level seroprevalence was 31.5% in round 1 (October-November 2020), after
31 India’s first COVID wave. Seroprevalence fell to 22.9% in 2 (April 2021), consistent with
32 waning of antibodies from natural infection. Seroprevalence rose to 67.1% by round 3 (June-
33 July 2021), reflecting infections from the Delta-variant induced second COVID wave.

34 Seroprevalence rose to 93.1% by round 4 (December 2021-January 2022), reflecting higher
35 vaccination rates. Antibodies also appear to wane after vaccination. Seroprevalence in urban
36 areas was higher than in rural areas, but the gap shrunk over time (35.7 v. 25.7% in round 1,
37 89.8% v. 91.4% in round 4) as the epidemic spread even in low-density rural areas.

38

39 **Keywords:** SARS-CoV-2, seroprevalence, waning antibodies, vaccination, India

40

41 **Introduction**

42 Knowledge of population-level immunity is critical for understanding the epidemiology
43 of SARS-CoV-2 (COVID-19) and formulating effective infection control, including the
44 allocation of scarce vaccines. Tamil Nadu is the 6th most populous state in India, with roughly
45 72 million persons ([1](#)). India, including Tamil Nadu, experienced three COVID-19 waves that
46 peaked in September 2020, May 2021, and February 2022 ([2](#)). India has reported 43 million
47 COVID-19 cases and 524,000 COVID-19 deaths through May 31, 2022 ([2](#)). Tamil Nadu has
48 reported roughly 3.4 million COVID-19 cases and 38,000 deaths, ranked 4th highest among
49 Indian states through May 31, 2022 ([3](#)). Reported cases are not, however, gathered from
50 population-representative samples. Moreover, low testing rates may cause cases to
51 underestimate population-level immunity.

52 To address these concerns, the state government conducted population-level serological
53 surveys in 4 rounds, in October-November 2020, April 2021, June-July 2021, December 2021-
54 January 2022 (Figure 1). Each survey was conducted on representative populations in each
55 district of the state, except Chennai in round 2. We report seroprevalence estimates from these
56 surveys by district, by demographic groups, and by urban status. We compare the results of the
57 surveys to estimates from reported cases to measure the degree to which reported cases
58 underestimate population immunity. We examine the extent to which infection and vaccination
59 contributes to seroprevalence by comparing rates of infection and vaccination to changes in
60 seroprevalence across rounds of surveys. We infer the extent to which antibodies decline
61 following infection and vaccination by using data on changes in district-level seroprevalence
62 across rounds and individual reports of the date of their own infection and vaccination,
63 respectively.

64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86

Methods

The study was approved by the Directorate of Public Health and Preventive Medicine, Government of Tamil Nadu, and the Institutional Ethics Committee of Madras Medical College, Chennai, India. The study was entirely funded by the Government of Tamil Nadu and the National Health Mission, Tamil Nadu.

Outcomes. The primary endpoints are (1) the fraction of the population that would obtain positive results on CLIA (chemiluminescent immunoassay) antibody tests for COVID, i.e., seropositivity, at the district-level, and (2) the fraction of the population that have antibodies for COVID, i.e., seroprevalence, district level.

The secondary endpoints are (1) seroprevalence (a) by age and sex, (b) by urban status, and (c) at the state level; (2) the difference between population immunity estimated by serological survey and by reported cases; and (3) self-reported infection and vaccination.

Survey timing, sample, and location. Data was gathered between 19 October – 30 November 2020, 7 – 30 April 2021, 28 June to 7 July 2021, 27 December 2021 – 6 January 2022 in rounds 1, 2, 3 and 4, respectively. Individuals residing in Tamil Nadu and ages 18 years and older were eligible for rounds 1 to 3 of this study. In round 4, eligibility was expanded to ages 10 and older. The exclusion criteria were refusal to consent and contraindication to venipuncture. In round 2, Chennai district was not surveyed because there was an outbreak that prevented sampling in that district.

Sample size. Sample sizes for rounds 1 to 3 were calculated assuming a seropositivity of 0.5 throughout the state, to maximize sample size. For round 4, the positivity rate estimated from round 3 (0.662) was used. Calculations sought a confidence level of 0.95. Because clustered sampling would be done, a design effect of 1.5 was applied in rounds 1 to 3 and of 2 in

87 round 4. The resulting sample size was multiplied by 37, the number of districts in Tamil Nadu
88 as of October 2020, for rounds 1 and 3. In round 2, the multiple was 36 because Chennai was
89 not sampled. In round 4, the multiple was 38, as one of the districts was split into two by round
90 4. This implied state-wide sample size targets were 26,651 in rounds 1 and 3, 25,931 in round 2,
91 and 32,664 in round 4.

92 **Sampling strategy.** The study selected participants in each district in five steps. *First*,
93 districts were divided into rural and urban strata. District-wise sample-size targets were
94 allocated to rural and urban strata in proportion to strata population. *Second*, rural and urban
95 strata were divided into geographic clusters, defined as a village and street segments in rural and
96 urban strata, respectively. *Third*, strata-wise sample-size targets were converted into cluster
97 sample-size targets assuming 30 persons were sampled per cluster. *Fourth*, random sampling
98 was used to select the targeted sample-size of clusters from each strata in each round. *Fifth*, up
99 to 30 were sampled from each cluster use a random starting point, systematic sampling of
100 households, and the Kish (4) method to select one participant per household. (Additional details
101 are in the Supplement).

102 **Data collection.** Each participant was asked to complete a health questionnaire
103 (including questions on prior infections and vaccination) and provide 5ml venous blood collected
104 in EDTA vacutainers. Serum was analyzed for IgG antibodies to the SARS-CoV-2 spike protein
105 using either the iFlash-SARS-CoV-2 IgG (Shenzhen YHLO Biotech; sensitivity of 95.9% and
106 specificity of 95.7% per manufacturer) (5) or the Vitros anti-SARS-CoV-2 IgG CLIA kit (Ortho-
107 Clinical Diagnostics; sensitivity of 90% and specificity of 100% per manufacturer) (6). We
108 obtained data on each reported COVID-19 case and death through May 2022 from the

109 Government of Tamil Nadu and Covid19Bharat.org (3) and on the number of tests done through
110 January 2022 from the Government of Tamil Nadu.

111 **Statistical analysis.** All statistics are calculated separately for each round unless
112 otherwise indicated.

113 *Seropositivity.* The proportion of positive CLIA tests by district is obtained by estimating
114 a logit regression of test result on district indicators and reporting the inverse logit of the
115 coefficient for each district indicator. Observations are weighted by the inverse of sampling
116 probability for their age and gender groups; the sampling probability here and below is based on
117 population counts from the 2011 Indian Census. We reweight to match the 2011 Census because
118 the Kish method ensures even (rather than representative) sampling by gender and age.
119 Clustered standard errors are calculated at the cluster level.

120 *Seroprevalence.* Seroprevalence by district is estimated in two steps. First, we calculate
121 the weighted proportion of positive tests at the district level. (We explain an exception for
122 Chennai in round 1 and Virudhunagar in round 3 in the Supplement.) All samples in a district
123 were tested using the same type of CLIA kit. We estimate a logit regression of test results on
124 district indicators and take the inverse logit of the coefficient for each jurisdiction indicator.
125 Observations are weighted by the inverse of sampling probability for their age and gender
126 groups. Clustered standard errors are calculated at the cluster level. Second, for each
127 jurisdiction, we predict seroprevalence using the Rogan-Gladen formula (Z), test parameters for
128 the kit used in each jurisdiction, and regression estimates of seropositive proportion by
129 jurisdiction.

130 State-level seroprevalence is obtained by aggregating the seroprevalence across districts
131 weighted by 2011 Census data on the relative populations of districts.

132 Seroprevalence by demographic group is estimated in three steps. *First*, we calculate the
133 proportion of positive tests at the jurisdiction-by-demographic group level in that round using
134 logit regressions of test results on jurisdiction-by-demographic group indicators. Demographic
135 groups indicators are sex x age for 6 age bins. Standard errors are clustered at the cluster level.
136 *Second*, we predict district-by-demographic group level seroprevalence using the Rogan-Gladen
137 formula. *Third*, we compute the weighted average of seroprevalence at the demographic-group
138 level using as weights the share of demographic-group population in each district using data
139 from the 2011 Indian census.

140 Seroprevalence by vaccine status in each of rounds 2 to 4 (when vaccines were available)
141 is estimated in the same manner we calculate seroprevalence by demographic group in a round,
142 except we replace demographic group by vaccine status.

143 Seroprevalence by urban status is obtained in the same manner as seroprevalence by
144 demographic group, with two changes. First, we use the urban status of a cluster in lieu of
145 demographic status of an individual at each step. Second, observations in our regression are
146 weighted by inverse of the sampling probability for their urban status.

147 The size of a population that was seropositive by the end of a round is obtained by
148 multiplying our seroprevalence estimates for the population in that round by the size of that
149 population (as reported in the 2011 Census).

150 *Undercounting of infections.* The degree of undercounting of infections in round 1 is
151 estimated by dividing the estimated number of people that are seropositive in the Tamil Nadu
152 population by the number of government-reported cases in that population as of 1 week before
153 the median sampling date of that round (23 October 2020). We focus on round 1 because
154 vaccinations started between after round 1 and some seropositivity in rounds 2 to 4 is due to

155 vaccination, not infections. The lag accounts for the delay, both between infection and
156 seropositive status and between infection and prevalence testing. We calculate the Pearson's
157 correlation coefficient between undercounting rate and testing rate (tests per million as of median
158 date of testing) by district.

159 *Waning antibodies.* We estimate the decline of antibodies after infection and in the
160 absence of vaccination using district-level observations and a linear regression of district-level
161 seropositivity in round 2 on district-level seropositivity in round 1. We focus on round 1 because
162 no participants were vaccinated before round 1, meaning all seropositivity is due to infection.
163 Observations are weighted in proportion to the population of each district in the 2011 Census.
164 To address the possibility that decay is masked by new infections or vaccinations, we estimate a
165 second specification that includes as controls a measure of the percent of population infected
166 between round 1 and round 2 and the fraction of respondents who self-report vaccination. The
167 measure of infection, which we call the “adjusted cases rate”, is the number of new confirmed
168 cases per capita between rounds 1 to 2, adjusted by the infection undercount rate in round 1
169 (seroprevalence rate in round 1 divided by cases per capita until round 1).

170 We estimate the decline of antibodies following two doses of vaccination in two steps.
171 *First*, we restrict the sample to individuals from round 4 who had been vaccinated with their
172 second dose at least at least 20 days prior to biosample collection. The 20-day delay is intended
173 to omit the period of time during which antibodies are climbing post-vaccination. We do not
174 consider individuals from round 2 because we do not have their date of vaccination and from
175 round 3 because so few individuals were vaccinated by that date. *Second*, we estimate a linear
176 regression with an indicator for whether a person was seropositive as the dependent variable and
177 the number of years (i.e., number of days/365) since dose 2 as the independent variable.

178 Observations are weighted to match age and gender proportions in the 2011 Census. To obtain
179 plausibly causal estimates, we use age as an instrumental variable (IV) for the number of days
180 since vaccination. The logic for this instrument is that Tamil Nadu prioritized individuals for
181 vaccination based on their age, with older age persons given greater priority; to validate this
182 instrument, we create a binscatter of days since vaccination on age among individuals with only
183 1 dose of vaccine and confirm that days since vaccination rises with age. The drawback of this
184 instrument is that it is possible that antibody decay is directly a function of age (8); therefore, IV
185 estimates should be taken with a grain of salt.

186 *Attribution to infection or vaccination.* We attribute the change in seropositivity from
187 round $t - 1$ to round t to changes in the levels of infections and of vaccination using the
188 formula:

$$189 \quad 1 = \frac{(s_t^v - s_{t-1}^v)p_{t-1}}{s_t - s_{t-1}} + \frac{(s_t^{nv} - s_{t-1}^{nv})(1 - p_{t-1})}{s_t - s_{t-1}} + \frac{(s_t^v - s_t^{nv})(p_t - p_{t-1})}{s_t - s_{t-1}}.$$

190 where s_t is the seropositivity rate in round t , p_t is the fraction of the sample vaccinated by round
191 t , s_t^v is the seropositivity rate among those vaccinated by round t , and s_t^{nv} is the seropositivity
192 rate among those not vaccinated by round t . The first term captures the share of the change in
193 seropositivity ($s_t - s_{t-1}$) attributable to changes in seropositivity rate among the previously
194 vaccinated ($s_t^v - s_{t-1}^v$). (This rate can change over time because antibodies levels may depend
195 on the number of days since vaccination.) The second term captures the share attributable to
196 infections among the previously unvaccinated ($1 - p_t$). The third term captures the share
197 attributable to changes in the vaccination rate. This captures both the effect of the increase in the
198 vaccination rate ($p_t - p_{t-1}$) and the change in seropositivity when one gets vaccinated ($s_t^v -$
199 s_t^{nv}). We calculate these components for the change in seropositivity from rounds 2 to 3 and
200 from rounds 3 to 4.

201 Statistical tests comparing groups are performed using a two-sided Wald test with 95%.
202 All statistical analyses were conducted with Microsoft Excel 365 (Microsoft, USA) and Stata 16
203 (StataCorp, USA). All plots were generated in R.

204

205 Results

206 **Sample.** In *round 1*, the study obtained results for 26,135 persons in 882 clusters (Table
207 1). The study could not sample 6 clusters and was unable to consent 324 persons in sampled
208 clusters. One person aged 16 was incorrectly consented and dropped from the analysis. In *round*
209 2, the study obtained results for 21,992 persons in 746 clusters. (Chennai was not sampled.) The
210 study could not sample 118 clusters and was unable to consent 388 persons in sampled clusters.
211 Twenty-six persons age <18 were incorrectly consented and dropped from the analysis. In *round*
212 3, the study obtained results for 26,592 persons. The study could not consent 48 persons in
213 sampled clusters. In *round 4*, the study obtained results for 32,244 persons. The study was
214 unable to sample 13 clusters and could not consent 56 persons in sampled clusters. The final
215 sample size per round was within the allowable 20% non-response rate.

216 Table 1 reports the demographic characteristics of the sample in each round. The sample
217 has substantially more females and fewer persons aged 10-17 and 18-29 and more elderly
218 persons than the general population.

219 **Seropositivity.** State-level seropositivity was 33.0% (95% CI: 32.0-34.0%), 23.1% (95%
220 CI: 22.2-24.0%), 67.5% (95% CI: 66.7-68.4%), and 88.3% (CI: 87.8-88.8%) in rounds 1, 2, 3
221 and 4, respectively (Table 2).

222 Seropositivity varied dramatically across districts in the first 3 rounds: from 11.9% (The
223 Nilgris) to 49.7% (Perambalur) in round 1, 11.3% (Ramanathapuram) to 49.5% (Tiruvallur) in

224 round 2, and 37.5% (Erode) to 81.9% (Chennai) in round 3 (Figure 2). Seropositivity converged
225 by round 4, ranging from 82.9% (Tirupathur) to 94.3% (Thiruvarur).

226 **Seroprevalence.** State-level seroprevalence was 31.6% (95% CI: 30.3-32.7%), 22.9%
227 (95% CI: 21.8-23.9%), 67.1% (95% CI: 65.9-68.3%), and 90.6% (CI: 90.1-91.1%) in rounds 1,
228 2, 3 and 4, respectively (Table 2). District-wise seroprevalence has a similar pattern to district-
229 wise seropositivity (Supplement Figure 1).

230 Seroprevalence was significantly greater in urban areas than rural areas in rounds 1
231 (35.7% v. 25.7%, $p < 0.001$) and round 3 (74.8% v. 64.1%, $p < 0.001$) (Table 2).

232 Urban classification of clusters was not available for round 2. By round 4, however, the gap has
233 largely closed (91.4% v. 89.8%, $p < 0.001$).

234 Seroprevalence is not substantially different across sexes (females v. males: 30.8% v.
235 30.2% in round 1; 22.0% v. 21.3% in round 2; 67.5% v. 65.5% in round 3; 92.7% v. 89.8%,
236 round 4) (Table 2). While the round 4 difference is significant ($p < 0.001$), it is still a small gap.

237 Seroprevalence is highest among older working-age populations in rounds 1 to 2 and
238 among younger populations in rounds 3 to 4. Seroprevalence is significantly higher among older
239 working-age populations than the elderly in rounds 1 to 3 (age 50-59 v. age 70+: 32.2% v.
240 26.5%, $p = 0.002$ in round 1; 25.6% v. 21.5%, $p = 0.006$ in round 2; 66.6% v. 59.6%, $p < 0.001$ in
241 round 3). Seroprevalence among young adult populations is significantly greater than among the
242 elderly in rounds 3 to 4 (18-29 v. 70+: 67.7% v. 59.6%, $p < 0.001$ in round 3; 92.2% v. 83.5%,
243 $p < 0.001$ in round 4) (Table 2). However, seroprevalence among the children aged 10-17 is
244 lowest of all in round 4 (66.4%, $p < 0.001$ v. each other age group).

245 Seroprevalence is significantly greater among vaccinated populations (25.7% v. 20.9%,
246 $p < 0.001$; 80.0% v. 62.3%, $p < 0.001$; and 93.1% v. 68.1%, $p < 0.001$ in rounds 2, 3, and 4,

247 respectively). Rounds 3 and 4 suggest that seroprevalence is increasing in number of doses taken
248 (0 doses v. 1 dose: 62.3% v. 77.5% ($p<0.001$) in round 1, and 68.1% v. 87.4% ($p<0.001$) in
249 round 2; 1 dose v. 2 doses: 77.5% v. 85.9% ($p<0.001$) in round 1 and 87.4% v. 95.0% ($p<0.001$)
250 in round 2) (Table 2).

251 **Undercounting.** The ratio of the number of infections implied by seroprevalence to
252 confirmed cases ranges widely across districts, from 10 to 148 in round 1 (Supplement Table S
253 2). There is a significant negative correlation ($\rho=-0.58$, $p<0.00$) between COVID testing rate per
254 thousand and the undercount rate in round 1 (Figure 3).

255 **Waning antibodies.** On average, district-wise seroprevalence rate in round 2 is 68.4% of
256 the seroprevalence rate in round 1 in a district (Table 3), implying a 31.6% decline in
257 seroprevalence, perhaps due to antibody waning. Across districts, the average adjusted cases rate
258 is 9.35% between rounds 1 and 2 and on average 17.8% of sample members report being
259 vaccinated with at least 1 dose by round 2. Adding (a) the district-level adjusted case rate to the
260 regression to control for seropositivity due to new infection and (b) the self-reported vaccination
261 rate to the regression to control for seropositivity due to vaccination yields a lower
262 seroprevalence rate of 42.7% of round 1, implying a significantly larger 57.3% decline ($p<0.001$)
263 in seroprevalence after infection.

264 The annual rate of antibody decay after vaccination among individuals given 2 vaccine
265 doses by round 4 is 16.3 percentage points after 1 year (Table 4). The seropositivity rate falls to
266 zero within a year with the use of age as an instrumental variable for time since dose 2 to obtain
267 causal estimates.

268 **Attribution to infection or vaccination.** Seropositivity increased by 42 percentage
269 points (p.p.) between rounds 2, just before India's second COVID wave, and round 3, after that

270 wave (Table 5). Infections accounted for 74% of this increase. Increased seropositivity among
271 those vaccinated by round 2 accounted for 23%, and new vaccinations accounted for just 2%.
272 Seropositivity increased 23 p.p. from round 3-4, the period between India's second and third
273 wave. New vaccinations accounted for 65% of this increase. New infections and greater
274 seropositivity among those vaccinated by round 3 accounted for 22% and 13% of this change.

275

276 **Discussion**

277 Serological surveillance suggests that officially confirmed cases dramatically
278 underestimate the number of infections before vaccination. Statewide seroprevalence in round 1
279 implies that at least 22.6 million persons in Tamil Nadu were infected after Tamil Nadu's first
280 wave (by 30 November 2020). This estimate of actual infections is roughly 35 times larger than
281 the number of confirmed cases by round 1 (674,802 cases by 16 October 2020) ([9](#)).

282 Antibody decline after infection implies that even serological surveillance may
283 underestimate actual infection rates before a vaccination campaign begins. Seropositivity
284 declined between 31.6 and 57.3% over the roughly 6 months (170 days) between rounds 1 and 2.
285 Evidence of cellular memory suggests that serological surveillance may also underestimate
286 population immunity to COVID-19 ([10](#)).

287 We also observe declining seropositivity – implying declining antibody counts -- after
288 vaccination. However, we only observe individuals for at most 6 months after last dose.
289 Therefore, one should not extrapolate from these data beyond one-half year. Moreover,
290 participants with the greatest time since vaccination are also older, and older people may
291 experience more rapid waning of antibodies ([8](#)). Therefore, caution should be taken before
292 extrapolating to younger populations.

293 Both infection and vaccination can contribute to seroprevalence. Between rounds 2 to 3,
294 India experienced a second COVID-19 wave due to the Delta variant ([11](#)). As a result, a
295 majority of the increase in seropositivity from 23.1 to 67.5% was attributable to new infections.
296 Between rounds 3 to 4, India ramped up its vaccination campaign and did not experience another
297 COVID-19 wave. Therefore, most of the increase in seropositivity to 88.3% was attributable to
298 vaccination.

299 The less-than-100% seropositivity rate or seroprevalence among the vaccinated, even
300 conditional on days since vaccination (Supplement Figure S2), suggests that either some
301 participants incorrectly reported being vaccinated or some doses may not have triggered a
302 detectable antibody response.

303 Our study has several limitations. First, because antibody concentrations in infected
304 persons decline over time ([12](#)), our estimate of seroprevalence in round 1 may underestimate the
305 level of prior infection and perhaps natural immunity.

306 Second, our estimate of antibody decline due to natural infection may be incorrect if our
307 adjusted reported case rate does not accurately estimate the infection rate across districts. In that
308 case, our control for infections in Table 3 is inadequate. The fact that a 1 percentage point
309 increase in that adjusted rate is associated with a 1 percentage point higher seropositivity rate,
310 however, suggests that the adjusted rate is a reasonable measure of infections.

311 Third, we may not accurately untangle seropositivity in round 3 that is due to infection
312 versus due to vaccination. Our estimate of seropositivity among the vaccinated and among the
313 unvaccinated during round 3 may be biased if there is selection into vaccination status that is
314 correlated with seropositivity.

315

316

Figures and tables

317

318 *Table 1. Demographics of sample, as compared to 2011 Census*

		Sample				Census 2011
		Oct-Nov 2020	Apr 2021	Jun-Jul 2021	Dec 2021- Jan 2022	
Gender	Male	39%	42%	42%	42%	50%
	Female	61%	58%	58%	58%	50%
Age	10-17				6%	16%
	18-29	23%	17%	19%	17%	26%
	30-39	23%	21%	23%	20%	19%
	40-49	20%	21%	22%	20%	16%
	50-59	16%	18%	18%	18%	11%
	60-69	11%	14%	12%	13%	8%
	70+	6%	8%	6%	7%	5%
Obs.		26,135	21,966	26,592	32,244	

Note. Census 2011 number for ages 18-29 includes only those ages 20-29.

319

320

321 *Table 2. Seroprevalence by type of region, sex, and age*

Variable	(1) October-November 2020			(2) April 2021			(3) June-July 2021			(4) Dec 2021-Jan 2022		
	Seroprevalence	CI lower bound	CI upper bound	Seroprevalence	CI lower bound	CI upper bound	Seroprevalence	CI lower bound	CI upper bound	Seroprevalence	CI lower bound	CI upper bound
State	32.4%	31.3%	33.6%	21.6%	20.6%	22.6%	69.2%	68.2%	70.2%	90.6%	90.1%	91.1%
Region												
Rural	25.7%	24.3%	27.0%				64.1%	62.9%	65.4%	89.8%	89.0%	90.6%
Urban	35.7%	34.0%	37.4%				74.8%	73.1%	76.6%	91.4%	90.7%	92.1%
Sex												
Male	30.2%	28.8%	31.7%	21.3%	20.0%	22.6%	65.5%	64.2%	66.7%	88.5%	87.7%	89.3%
Female	30.8%	29.5%	32.0%	22.0%	20.8%	23.1%	67.5%	66.2%	68.7%	92.7%	92.1%	93.3%
Age												
10-17										69.1%	66.4%	71.8%
18-29	30.4%	28.7%	32.2%	19.5%	17.8%	21.1%	67.7%	66.1%	69.3%	92.2%	91.3%	93.2%
30-39	30.7%	29.0%	32.5%	21.2%	19.6%	22.8%	67.0%	65.4%	68.6%	90.7%	89.7%	91.8%
40-49	31.7%	30.0%	33.5%	22.1%	20.4%	23.9%	66.7%	65.0%	68.4%	91.8%	90.9%	92.7%
50-59	32.2%	30.3%	34.1%	25.6%	23.8%	27.4%	66.6%	64.8%	68.5%	89.7%	88.7%	90.7%
60-69	28.4%	26.2%	30.5%	22.8%	21.0%	24.6%	65.0%	62.8%	67.2%	87.8%	86.6%	89.1%
70+	26.5%	23.7%	29.2%	21.5%	19.0%	23.9%	59.6%	56.8%	62.3%	83.5%	81.6%	85.3%
Vaccine doses												
0	30.5%	29.4%	31.6%	20.9%	19.9%	22.0%	62.3%	61.2%	63.3%	68.1%	65.8%	70.4%
1	-	-	-	25.7%	23.3%	28.1%	77.5%	75.6%	79.4%	87.4%	86.3%	88.4%
2	-	-	-	-	-	-	85.9%	83.3%	88.4%	95.0%	94.5%	95.6%

322

323 *Table 3. Decay of antibodies following natural infection*

	(1)	(2)
	Dependent variable: Seroprevalence in round 2	
Seroprevalence in round 1	0.684*** (0.0635)	0.427** (0.129)
Adjusted case count		1.204** (0.370)
Fraction vaccinated with 1 dose by round 2		-0.143 (0.161)
N	36	36

Notes. This table presents the results from regressing seroprevalence at the district level in round 2 against seroprevalence at the district level in round 1 and no constant. In column 2, the regression also includes the district-level adjusted case rate between round 1 and 2 to capture new COVID infections and the fraction vaccinated with 1 dose (self-reported) by round 2 to capture the new vaccination rate.

324

325 *Table 4. Decay of antibodies following vaccine dose*

	(1)	(2)
	Dependent variable: Seropositivity in round 4	
Years since dose 2	-0.163*** (0.0125)	-1.001*** (0.150)
Constant	0.960*** (0.00368)	1.161*** (0.0359)
N	15676	15676
Total doses	2 doses	2 doses
Instruments	-	Age

Notes. This table presents results from regressing seropositivity against years since second dose of vaccine. In the second column, years since last dose is instrumented by age.


326

327 *Table 5. Attribution of seropositivity trends to infection or vaccination*

	Change in seropositivity ($s_t - s_{t-1}$)	Antibody response given vaccination ($s_t^v - s_{t-1}^v$) p_{t-1}	Infection given no vaccination ($s_t^{nv} - s_{t-1}^{nv}$) \times (1 - p_{t-1})	New vaccinations ($s_t^v - s_t^{nv}$) \times ($p_t - p_{t-1}$)
Round 2 to Round 3:				
Percentage points	42	9.6	31.1	1.1
Percent of ($s_t - s_{t-1}$)		23%	74%	3%
Round 3 to Round 4:				
Fraction	23	3.0	5.2	15.1
Percent of ($s_t - s_{t-1}$)		13%	22%	65%

328


329 *Figure 1. Daily new infections, new vaccinations (dose 1), and dates of serological survey*
330 *rounds in Tamil Nadu*



331

332

336 *Figure 3. Relationship between rate of undercounting and testing rate in Round 1*



337

338

339 **Author contributions:** The study design and sampling were conceived, led and carried out by
340 the Directorate of Public Health and Preventive Medicine, Government of Tamil Nadu, for the
341 Government of Tamil Nadu’s Department of Health and Family Welfare. Data cleaning was
342 performed by Vaidehi Tandel, Rajeshwari Parasa, and Sabareesh Ramachandran. Statistical
343 analysis was conducted by Sabareesh Ramachandran and Anup Malani. Writing was done by
344 Anup Malani, Sabareesh Ramachandran, and Stuti Sachdeva.

345

346 **Disclaimers:** The opinions expressed by authors contributing to this journal do not necessarily
347 reflect the opinions of the Centers for Disease Control and Prevention or the institutions with
348 which the authors are affiliated.

349

350 **Address for Correspondence:** Anup Malani, University of Chicago, 1111 E. 60th Street,
351 Chicago, IL 60637; (773) 702-9602; (773) 702-0730 (fax), amalani@uchicago.edu.

352

353

354 **SUPPLEMENTAL MATERIALS**

355 **Seroprevalence in Tamil Nadu in October-November 2020**

356
357 Selvavinayagam T.S., Somasundaram A., Jerard Maria Selvam,
358 Sabareesh Ramachandran, Sampath P., Vijayalakshmi V., Ajith Brabhu Kumar C.,
359 Sudharshini Subramaniam, Raju. S, Avudaiselvi. R, Prakash V., Yogananth N.,
360 Gurunathan Subramanian, Roshini. A, Dhiliban D.N., Sofia Imad, Vaidehi Tandel,
361 Rajeswari Parasa, Stuti Sachdeva, Anup Malani*

362

363 **Methods**

364 **Sample.** Suspected or confirmed current or prior COVID-19 infection was not an
365 exclusion criterion. If a participant was currently receiving medical care for COVID-19, a
366 family member or proxy was used to complete the questionnaire on the participant's behalf;
367 however, the blood sample was taken from the participant.

368 **Sampling strategy.** The study selected participants in each district in five steps. *First*,
369 districts were divided into rural and urban strata. All human settlements labeled villages in the
370 2011 Indian Census made up the rural strata. In rounds 1 to 3, the remaining settlements were
371 the urban strata. (In round 4, the urban strata was further stratified into substrata comprised of

* Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu: Selvavinayagam, T.S., Somasundaram A., Jerard Maria Selvam, Sampath P., Vijayalakshmi V., Ajith Brabhu Kumar C., Sudharshini Subramaniam, S. Raju, Avudaiselvi, Prakash V., Yogananth N., Roshini, and Dhilipan; University of California, San Diego: Sabareesh Ramachandran; IDFC Institute: Sofia Imad. Rajeshwari Parasa; Independent: Vaidehi Tandel and Stuti Sachdeva; University of Chicago: Anup Malani. Corresponding author (amalani@uchicago.edu).

372 municipal wards to make sure sampling was more geographically representative.) *Second*, rural
373 and urban strata and substrata were divided into so-called clusters. In rural areas, each village
374 was a single cluster. In urban areas, a street segment including between 50-500 households was
375 called a cluster. *Third*, district-wise individual sample-size targets were converted into district-
376 wise cluster sample-size targets assuming that 30 persons would be sampled per cluster. Clusters
377 sample targets were assigned to rural and urban strata and substrata in proportion to the
378 population of those strata. *Fourth*, simple random sampling was used to select the actual clusters
379 to be sampled in accordance with cluster sample-size targets for each rural and urban strata or
380 substrata.

381 *Finally*, within each cluster, a random GPS starting point was selected. One participant
382 per household was sampled from households adjacent to that starting point until 30 persons
383 consented within a cluster. Within each household, the participant asked to provide a biosample
384 was selected via the Kish method (4). If a participant refused, the survey went to next adjacent
385 house until either 30 participants consented in the cluster or there were no more households in
386 the cluster, whichever came first. The study asked participants using this process separately in
387 each of the three rounds of survey; therefore, the participants sampled in each round may not be
388 the same people sampled in other rounds.

389 **Data collection.** Blood was collected in EDTA vacutainers. Serum was isolated and
390 stored in Eppendorf tubes. Serum was analyzed using either of two chemiluminescent
391 immunoassay (CLIA) kits.

392 The first kit was the iFlash-SARS-CoV-2 IgG kit from Shenzhen YHLO Biotech. Per the
393 manufacturer, it has a sensitivity of 95.9% (95% CI: 93.3-97.5%) and specificity of 95.7% (95%

394 CI: 92.5-97.6%) ([5](#)). Independent analysis estimated a sensitivity of 93% (95% CI: 84.3–97.7%)
395 and specificity of 92.9% (95% CI: 85.3–97.4%) ([13](#)).

396 The second kit was the Vitros anti-SARS-CoV-2 IgG CLIA from Ortho-Clinical
397 Diagnostics. Per the manufacturer it has 90% sensitivity (95% CI: 76.3-97.2%) and 100%
398 specificity (95% CI: 99.1–100.0%) ([6](#)). FDA evaluation suggests it has 100% sensitivity (95%
399 CI: 88.7-100%) and 100% specificity (95% CI: 95.4-100%) ([14](#)). Independent analysis
400 estimated that it has a sensitivity of 98.8% (95% CI: 92.9-100%) and specificity of 97.3% (95%
401 CI: 85-100%) ([15](#)).

402 All the samples in a district are analyzed using the same kit in a round, with the exception
403 of Chennai in round 1 and Virudhunagar in round 3, where different HUDs used different kits.
404 Table S 1 reports the test kit used in each district.

405 **Statistical analysis.** Generally, Nagapattinam district was split into Nagapattinam and
406 Mayiladuthurai districts in March 2020, after the state started reported data on confirmed cases
407 but before we conducted our serological survey. We aggregate these two districts together in our
408 estimates of seropositivity and seroprevalence.

409 In Chennai, we do not have the population by HUDs. Since the samples were drawn
410 proportional to population, we divide the district population across the HUDs in proportion to the
411 sample size.

412 *Seroprevalence.* When estimating our district-level seroprevalence, the weights for our
413 regression analysis employ data from the 2011 Census for the population in each age x gender
414 category in each district. We estimate the sampling probability for demographic group (age
415 category x sex) as the number of observations in that group in the sample in a district divided by
416 the census population in that group in a district.

417 When estimating our urban- and rural-level seroprevalence, the weights for our
418 regression analysis employ data from the 2011 Census for the population in each urban/rural
419 category in each district. We estimate the sampling probability for urban/rural group as the
420 number of observations in that group in the sample in a district divided by the census population
421 in that group in a district.

422 We calculate the sampling probabilities for each regression observation at the level of
423 2011-defined districts (of which there are 32) rather than the 2020/21-defined districts (of which
424 there are 37 or 38 depending on round), HUDs or clusters because the population is available
425 only at the level of the old 32 districts. Likewise, we calculate district weights when we
426 aggregate estimates across districts using the thirty-two 2001 districts. The 37 or 38, 2020/21
427 districts are all the same or bifurcations of the 2011 districts. Fortunately, in all bifurcated
428 districts, the same kit was used. Therefore, we can combine all bifurcated districts into older
429 2011 districts for purposes of calculating sampling probabilities in regression analyses or weights
430 when aggregating estimates.

431 Calculation of seroprevalence by district was modified in Chennai in round 1 and
432 Virudhunagar in round 3. All samples in a district were tested using the same type of CLIA kit,
433 except in Chennai and Virudhunagar, where all samples in a HUD were tested with the same
434 type of kit. *The first step* was to calculate the weighted proportion of positive tests at the level of
435 a health unit district (HUD), an administrative subset of districts. We estimate a weighted logit
436 regression of test results on HUD indicators in Chennai and Virudhunagar and take the inverse
437 logit of the coefficient for each jurisdiction indicator. Observations are weighted by the inverse
438 of sampling probability for their age and gender groups. Clustered standard errors are calculated
439 at the cluster level. *The second step*, for each jurisdiction, entailed predicting seroprevalence

440 using the Rogan-Gladen formula (7), test parameters for the kit used in each jurisdiction, and
441 regression estimates of seropositive proportion by jurisdiction. In Chennai and Virudhunagar
442 districts, we calculate seroprevalence at the district level as a weighted average of seroprevalence
443 at the HUD level, using as weights the share of clusters in each HUD. We employ this approach
444 to Chennai and Virudhunagar in estimators that use district-level seroprevalence.

445 *Attribution of changes in seropositivity to infection or vaccination.* The formula used to
446 attribute the change in seropositivity rate across arms to infection and vaccination is derived as
447 follows. First, we decompose the seropositivity rate s_t in round t into the fraction p_t of the
448 sample vaccinated by round t , the seropositivity rate s_t^v among those vaccinated by round t , and
449 the seropositivity rate s_t^{nv} among those not vaccinated by round t :

$$450 \quad s_t = s_t^v p_t + s_t^{nv} (1 - p_t).$$

451 The difference between the seropositivity rate in round t and $t - 1$ is

$$452 \quad \Delta s_t = s_t - s_{t-1} = [s_t^v - s_{t-1}^v] p_{t-1} + (s_t^v - s_t^{nv}) [p_t - p_{t-1}] + [s_t^{nv} - s_{t-1}^{nv}] (1 - p_{t-1}).$$

453 Dividing each side by the change in seropositivity across arms yields the fraction of changes in
454 seropositivity attributable to changes in the seropositivity rate give vaccination, changes in the
455 seropositivity rate given no vaccination, and, critically the increase in the vaccination rate:

$$456 \quad 1 = \frac{(s_t^v - s_{t-1}^v) p_{t-1}}{\Delta s_t} + \frac{(s_t^{nv} - s_{t-1}^{nv}) (1 - p_{t-1})}{\Delta s_t} + \frac{(s_t^v - s_t^{nv}) (p_t - p_{t-1})}{\Delta s_t}.$$

457

458

459

Figures and tables

460

461 *Table S 1. Test kit used in each district.*

District	Type of Kit	District	Type of Kit
Ariyalur	CPC Kit	Ramanathapuram	CPC Kit
Chengalpattu	Ortho Kit	Ranipet	Ortho Kit
Chennai	CPC & Ortho kits*	Salem	Ortho Kit
Coimbatore	Ortho Kit	Sivagangai	CPC Kit
Cuddalore	CPC Kit	Tenkasi	CPC Kit
Dharmapuri	Ortho Kit	Thanjavur	CPC Kit
Dindigul	CPC Kit	The Nilgiris	Ortho Kit
Erode	Ortho Kit	Theni	CPC Kit
Kallakurichi	CPC Kit	Thiruchirappalli	CPC Kit
Kancheepuram	Ortho Kit	Thiruvarur	CPC Kit
Kanniyakumari	CPC Kit	Thoothukudi	CPC Kit
Karur	CPC Kit	Tirunelveli	CPC Kit
Krishnagiri	Ortho Kit	Tirupathur	Ortho Kit
Madurai	CPC Kit	Tiruppur	Ortho Kit
Mayiladuthurai	CPC Kit	Tiruvallur	Ortho Kit
Nagapattinam	CPC Kit	Tiruvannamalai	Ortho Kit
Namakkal	Ortho Kit	Vellore	CPC & Ortho Kits*
Perambalur	CPC Kit	Villupuram	CPC Kit
Pudukkottai	CPC Kit	Virudhunagar	CPC & Ortho Kits*

Notes. 33 out of 122 clusters in Chennai used the CPC test kit in round 1. In round 3, all clusters in Chennai used the Ortho kit. Virudhunagar used only the CPC kit in rounds 1 and 2. In round 3, in 15 out of 23 clusters in Virudhunagar CPC kits were used. In Vellore Ortho kits were used in rounds 1 and 2 and Ortho kits in round 3. In round 4 Ortho kits were used in all districts.

462

463


464 *Table S 2. Confirmed cases and undercount of infections by district in round 1.*

District	Round 1 (Oct-Nov 2020)		
	Sero-prevalence	Total cases till survey	Under count
Ariyalur	0.263	4191	50
Chengalpattu	0.345	40241	23
Chennai	0.409	207390	10
Coimbatore	0.204	37932	20
Cuddalore	0.331	22170	41
Dharmapuri	0.192	4954	62
Dindigul	0.27	9465	65
Erode	0.185	8644	51
Kallakurichi	0.386	9802	57
Kancheepuram	0.337	23941	17
Kanniyakumari	0.351	14158	49
Karur	0.158	3664	49
Krishnagiri	0.189	5857	64
Madurai	0.379	18014	68
Nagapattinam	0.224	5959	64
Namakkal	0.172	7845	40
Perambalur	0.497	2010	148
Pudukkottai	0.252	10001	43
Ramanathapuram	0.351	5778	87
Ranipet	0.448	14326	40
Salem	0.224	25144	33
Sivagangai	0.268	5580	68
Tenkasi	0.472	7702	91
Thanjavur	0.27	14486	47
The Nilgiris	0.111	5510	16
Theni	0.444	15888	37
Thiruchirappalli	0.328	11645	81
Thiruvarur	0.215	8620	33
Thoothukudi	0.377	14391	49
Tirunelveli	0.435	13684	56
Tirupathur	0.238	5843	48
Tiruppur	0.197	10209	51
Tiruvallur	0.347	35320	39
Tiruvannamalai	0.361	16804	56
Vellore	0.28	16854	28
Villupuram	0.324	12712	56
Virudhunagar	0.379	14980	52

465


469 *Figure S2. Decline in seropositivity by day since vaccine dose*

470 *A: Participants who received exactly 1 dose*



471

472 *B: Participants who received exactly 2 doses*



473

474 **References**

- 475
- 476 1. Wikipedia. List of states and union territories of India by population. Wikipedia 2020
477 [cited 2021 January 4, 2021]; Available from:
478 https://en.wikipedia.org/wiki/List_of_states_and_union_territories_of_India_by_population
- 479 2. Johns Hopkins University & Medicine. COVID-19 Dashboard by the Center for Systems
480 Science and Engineering (CSSE) at Johns Hopkins University (JHU); 2022.
- 481 3. DataKind Bengaluru, Development Data Lab. Covid19Bharat.org. 2022 [cited 2022
482 May 31, 2022]; Available from: <https://covid19bharat.org/>
- 483 4. Kish L. A Procedure for Objective Respondent Selection within the Household. Journal
484 of the American Statistical Association. 1949 1949/09/01;44(247):380-7.
- 485 5. Shenzhen YHLO Biotech Co. Ltd. Customer Notification: Sensitivity and Specificity of
486 iFlash-SARS-Cov-2 IgG and IgM kits from Clinical Trials 2020.
- 487 6. Ortho Clinical Diagnostics. INSTRUCTIONS FOR USE - CoV2G (Version 4.2); 2020.
- 488 7. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test.
489 American journal of epidemiology. 1978;107(1):71-6.
- 490 8. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune
491 Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of
492 Medicine. 2021 2021/12/09;385(24):e84.
- 493 9. Covid19India. COVID19INDIA. 2022 [cited 2022 May 30, 2022]; Available from:
494 <https://www.covid19india.org/>
- 495 10. Moss P. The T cell immune response against SARS-CoV-2. Nature Immunology. 2022
496 2022/02/01;23(2):186-93.

- 497 11. World Health Organization. COVID-19 Weekly Epidemiological Update. 2021.
- 498 12. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody
499 response to SARS-CoV-2 infection in humans: A systematic review. PLOS ONE.
500 2021;15(12):e0244126.
- 501 13. Plebani M, Padoan A, Negrini D, Carpinteri B, Sciacovelli L. Diagnostic performances
502 and thresholds: The key to harmonization in serological SARS-CoV-2 assays? Clinica Chimica
503 Acta. 2020 2020/10/01/;509:1-7.
- 504 14. U.S. Food and Drug Administration. Serology Test Evaluation Report for “VITROS
505 Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack” from Ortho-Clinical
506 Diagnostics, Inc.; 2020 October 3, 2020.
- 507 15. Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four High-
508 Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. Journal of
509 Clinical Microbiology. 2020;58(8):e01243-20.
- 510